6.2957

0.64% -0.0443

Omeros Corporation (OMER)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Omeros Corporation stock is traded at $6.2957, with a volume of 14,106. It is down -0.64% in the last 24 hours and down -8.64% over the past month. Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Previous Close:

$6.34

Open:

$6.33

24h Volume:

14,106

Relative Volume:

0.02

Market Cap:

$420.39M

Revenue:

Net Income/Loss:

$-117.81M

P/E Ratio:

-3.3488

EPS:

-1.88

Net Cash Flow:

$74.30M

1W Performance:

-14.29%

1M Performance:

-8.64%

6M Performance:

+39.99%

1Y Performance:

+73.06%

1-Day Range:

$6.27

$6.3795

1-Week Range:

$6.265

$7.37

52-Week Range:

$3.0001

$13.60

Omeros Corporation Stock (OMER) Company Profile

Name

Omeros Corporation

Sector

Healthcare (1167)

Industry

Biotechnology (664)

Phone

206-676-5000

Address

201 ELLIOTT AVENUE WEST, SEATTLE, WA

Employee

202

Twitter

@OmerosCorp

Next Earnings Date

2025-03-31

Latest SEC Filings

OMER's Discussions on Twitter

Compare OMER with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OMER Omeros Corporation	6.29	420.39M	0	-117.81M	74.30M	-1.88
VRTX Vertex Pharmaceuticals Inc	442.12	129.44B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.70	61.42B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	621.07	38.44B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.44	33.29B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	234.01	26.95B	3.81B	-644.79M	-669.77M	-6.24

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Initiated	D. Boral Capital	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Dec-08-22	Downgrade	UBS	Buy → Neutral
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Sep-27-21	Initiated	JP Morgan	Neutral
Feb-01-21	Initiated	UBS	Buy
Oct-20-20	Initiated	BofA Securities	Buy
Aug-21-20	Reiterated	H.C. Wainwright	Buy
Aug-14-20	Reiterated	Maxim Group	Buy
May-06-19	Initiated	Cantor Fitzgerald	Overweight
Jul-12-18	Initiated	Seaport Global Securities	Buy
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral
Mar-17-17	Reiterated	Maxim Group	Buy
Mar-17-17	Reiterated	Needham	Buy
Nov-16-16	Reiterated	Wedbush	Outperform
Nov-10-16	Reiterated	Needham	Buy
Aug-10-16	Reiterated	Maxim Group	Buy
Jun-03-16	Initiated	Cantor Fitzgerald	Buy
Mar-02-16	Reiterated	Needham	Buy
Feb-29-16	Reiterated	Wedbush	Outperform
Nov-11-15	Reiterated	Needham	Buy
Aug-18-15	Reiterated	WBB Securities	Strong Buy
Aug-10-15	Initiated	ROTH Capital	Buy

View All

Omeros Corporation Stock (OMER) Latest News

09:01 AM

Market Update: Omeros Corporation (OMER) Sees Negative Movement, Closing at 6.34 - DWinneX

09:01 AM

08:00 AM

Omeros (OMER) Stock Rating and Price Target Maintained by Analyst | OMER Stock News - GuruFocus

08:00 AM

May 06, 2025

FDA Accepts Omeros (OMER) Resubmission for Narsoplimab Label Exp - GuruFocus

May 06, 2025

Omeros announces FDA acceptance of narsoplimab BLA resubmission - TipRanks

May 06, 2025

FDA Accepts Omeros (OMER) Resubmission for Narsoplimab Label Expansion - GuruFocus

May 06, 2025

Omeros gets FDA acceptance for narsoplimab BLA resubmission - Seeking Alpha

May 06, 2025

FDA Reviews Omeros' (OMER) Resubmission for Narsoplimab Approval | OMER Stock News - GuruFocus

May 06, 2025

FDA reviews Omeros drug for stem cell transplant complication By Investing.com - Investing.com India

May 06, 2025

FDA Sets September Decision Date for Narsoplimab: New Hope for Fatal Transplant Complication - Stock Titan

May 06, 2025

Barclays PLC Grows Holdings in Omeros Co. (NASDAQ:OMER) - Defense World

May 06, 2025

May 05, 2025

Invesco Ltd. Reduces Position in Omeros Co. (NASDAQ:OMER) - Defense World

May 05, 2025

May 03, 2025

JPMorgan Chase & Co. Has $317,000 Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World

May 03, 2025

May 02, 2025

Ratio Revelations: Omeros Corporation (OMER)’s Financial Metrics in the Spotlight - DWinneX

May 02, 2025

Omeros Corporation Inc. (OMER) Price Performance: A Fundamental Analysis Perspective - investchronicle.com

May 02, 2025

How should investors view Omeros Corporation (OMER)? - uspostnews.com

May 02, 2025

Apr 28, 2025

Omeros Corporation’s Market Journey: Closing Weak at 7.91, Down -3.77 - DWinneX

Apr 28, 2025

Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Apr 28, 2025

Apr 27, 2025

Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Apr 27, 2025

Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market - Barchart.com

Apr 27, 2025

Apr 24, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 24, 2025